Главная

О журнале |  Архив |  Текущий номер |  Подписка |  Авторам |  Контакты      


Журнал "Проблемы стандартизации в здравоохранении"

ИСПОЛЬЗОВАНИЕ ИНСТРУМЕНТОВ РАЗДЕЛЕНИЯ РИСКОВ И ПРОЦЕДУР РАННЕГО ДОСТУПА К ЛЕЧЕНИЮ В ЕВРОПЕЙСКОМ СОЮЗЕ
Лэшек Борковски, И.Ю. Солодун, М.А. Холовня, Е.П. Евдошенко
Больница Вольского, г. Варшава, Польша
Центр координации и проведения клинических исследований Департамента здравоохранения города Москвы

USE OF INSTRUMENTS OF RISK SHARING AND SCHEMES OF EARLY ACCESS TO TREATMENT IN THE EUROPEAN UNION
Leszek Borkowski, I.Y. Solodun, М.А. Holownia, Е.P. Evdoshenko
Wolski Hospital, Warsaw, Poland
State Budgetary Institution of Moscow City «Center of Clinical Trials Management and Performance of Moscow Department of Healthcare», Moscow, Russia

ЛИТЕРАТУРА

  1. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems (OJ No L 40 of 11. 2. 1989 p. 8), Доступно по: http://ec.europa.eu/health/files/eudralex/vol-1/dir_1989_105/dir_1989_105_en.pdf. Ссылка активна на: 20.05.2016.
  2. REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1). Доступно по: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Ссылка активна на: 20.05.2016.
  3. Communication for the Commission to the European Parliament, The Council, The European Economic Committee  and the Committee of the Regions on Rare Diseases Europe’s challenges 2008, 679. Доступно по: http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf. Ссылка активна на: 20.05.2016.
  4. Council Recommendation of 8 June 2009 on an action in the field of rare diseases 2009/C151/02, доступно на сайте. Доступно по: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF. Ссылка активна на: 20.05.2016.
  5. Edpin J. Analysis of differences and commonalities in pricing and reimbusement system in Europe materia? EU 2007.
  6. Carlson J et. al. Peyment to health outcomes:a taxonomy and examination of performabce-based reimbursement schemes between healthcare payers and manufacturers. Health Policy, 2008.
  7. Landa. K. et. al.: Pricing, ceny lek?w refundowanych, negocjacje i podzia? ryzyka. CEESTAHC Warszawa/Krak?w 2009.
  8. Carlson J. et. al. Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufactures. Health Policy. 2010.
  9. Klemp M. et al. What principles should govem the use of managed entry agreements. Int. J.Technol. Assess Health Care. 2011; 27 (1): 77-83.



Programming & design
by I.S.0pаrin